Connor, Clark & Lunn Investment Management Ltd. Insmed Inc Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$22.0 - $69.71 $883,850 - $2.8 Million	-40,175 Reduced 48.94%	41,908 $2.81 Million
Q1 2024 May 09, 2024	SELL	$25.72 - $29.94 $4.87 Million - $5.67 Million	-189,229 Reduced 69.75%	82,083 $2.23 Million
Q4 2023 Feb 09, 2024	SELL	$23.42 - $31.74 $4.09 Million - $5.55 Million	-174,792 Reduced 39.18%	271,312 $8.41 Million
Q3 2023 Nov 13, 2023	SELL	$19.86 - $26.93 $781,590 - $1.06 Million	-39,355 Reduced 8.11%	446,104 $11.3 Million
Q2 2023 Aug 10, 2023	SELL	$16.44 - $21.1 $508,242 - $652,306	-30,915 Reduced 5.99%	485,459 $10.2 Million
Q1 2023 May 09, 2023	SELL	$16.26 - $21.73 $161,055 - $215,235	-9,905 Reduced 1.88%	516,374 $8.8 Million
Q4 2022 Feb 10, 2023	BUY	$16.98 - $23.15 $5.49 Million - $7.49 Million	323,503 Added 159.54%	526,279 $10.5 Million
Q3 2022 Nov 10, 2022	BUY	$20.88 - $28.21 $3.23 Million - $4.36 Million	154,711 Added 321.88%	202,776 $4.37 Million
Q2 2022 Aug 05, 2022	BUY	$17.07 - $25.71 $600,949 - $905,120	35,205 Added 273.76%	48,065 $948,000
Q1 2022 May 12, 2022	BUY	$20.42 - $28.13 $262,601 - $361,751	12,860 New	12,860 $302,000

Others Institutions Holding INSM

# of Institutions

467

Shares Held

182M

Call Options Held

2.27M

Put Options Held

3.33M

Vanguard Group Inc Valley Forge, PA

17.1M
Shares

$1.27 Billion
0.02% of portfolio
Black Rock Inc. New York, NY

14.3M
Shares

$1.05 Billion
0.02% of portfolio
Price T Rowe Associates Inc Baltimore, MD

12.6M
Shares

$929 Million
0.11% of portfolio
Darwin Global Management, Ltd. St. Helier, Y9

10.5M
Shares

$775 Million
62.32% of portfolio
Capital International Investors Los Angeles, CA

6.52M
Shares

$482 Million
0.09% of portfolio

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $10B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account